National Comprehensive Cancer Network
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Contenu en anglais
Résumé
Thymomas and thymic carcinomas are rare mediastinal tumors that originate in the thymus. Patients with thymoma may experience symptoms associated with autoimmune paraneoplastic diseases (such as myasthenia gravis), which typically do not occur in patients with thymic carcinoma. The NCCN Guidelines for Thymomas and Thymic Carcinomas provide guidance for the diagnosis, treatment, and surveillance of patients with thymoma and thymic carcinoma. Involvement of a multidisciplinary team with experience treating thymomas and thymic carcinomas is highly recommended.
Source et droits
Publiée par Journal of the National Comprehensive Cancer Network : JNCCN, 2025. La recommandation elle-même se trouve à la source indiquée ici.
Prognia résume cette recommandation à des fins de consultation et d’enseignement. Il ne s’agit pas d’un avis médical. Vérifiez toujours la recommandation officielle et les protocoles locaux en vigueur avant de l’appliquer.
En bref
- Organisme
- National Comprehensive Cancer Network
- Date de publication
- 2025
- S’applique à
- 🇺🇸 États-Unis
- Portée
- Nationale
- Revue
- Journal of the National Comprehensive Cancer Network : JNCCN
- PubMed
- 40499586
Autres recommandations en oncologie
- Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyNational Comprehensive Cancer Network · 2026
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance) [2] · 2026
